Medical Education by Indication
Interactive case-based sessions spanning solid tumors, hematologic malignancies, dermatology, and beyond. These are some of the indications we cover — not all of them. If you don't see your area, reach out.
Oncology Indications
Interactive virtual sessions covering the major solid tumor types — from biomarker-driven therapy selection to resistance management and supportive care.
Metastatic Colorectal Cancer
Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Non-Small Cell Lung Cancer
Biomarker-driven first-line therapy selection in advanced NSCLC
Small Cell Lung Cancer
First-line immunotherapy-chemotherapy in extensive-stage SCLC
Prostate Cancer
Treatment intensification in metastatic hormone-sensitive prostate cancer
Ovarian Cancer
First-line treatment and PARP inhibitor maintenance in ovarian cancer
Endometrial Cancer
Molecular classification and its role in adjuvant therapy decisions
Melanoma
First-line immunotherapy in advanced melanoma: nivolumab-ipilimumab and beyond
Renal Cell Carcinoma
First-line IO-TKI combinations: selecting the right regimen
Bladder & Urothelial Cancer
Perioperative immunotherapy in muscle-invasive bladder cancer
Pancreatic Cancer
First-line therapy selection in metastatic pancreatic cancer
Hepatocellular Carcinoma
First-line immunotherapy combinations in advanced HCC
Head & Neck Squamous Cell Carcinoma
First-line immunotherapy in recurrent/metastatic HNSCC
Gastric & GEJ Cancer
Biomarker-driven first-line therapy in advanced gastric/GEJ cancer
Cholangiocarcinoma & Biliary Tract Cancer
First-line immunotherapy-chemotherapy in advanced biliary tract cancer
Esophageal Cancer
First-line immunotherapy-chemotherapy in advanced esophageal cancer
Cervical Cancer
First-line immunotherapy-chemotherapy-bevacizumab in advanced cervical cancer
Glioblastoma & Brain Tumors
MGMT-stratified treatment approaches in newly diagnosed glioblastoma
Thyroid Cancer
RET-targeted therapy in advanced thyroid cancer: selpercatinib and pralsetinib
Soft Tissue Sarcoma
Histology-driven first-line treatment selection in advanced soft tissue sarcoma
Hematology Indications
Case-based sessions covering leukemias, lymphomas, and plasma cell disorders — with a focus on targeted therapy integration and treatment sequencing.
Chronic Lymphocytic Leukemia
First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
Molecular-guided frontline therapy selection in AML
Myelodysplastic Syndromes
IPSS-M and molecular risk stratification in MDS
Follicular Lymphoma
First-line treatment selection: bendamustine-rituximab vs lenalidomide-rituximab
Myeloproliferative Neoplasms & Myelofibrosis
Risk-stratified first-line JAK inhibitor selection in myelofibrosis
Mantle Cell Lymphoma
Frontline MCL: intensive vs less-intensive chemoimmunotherapy with maintenance
Chronic Myeloid Leukemia
Risk-adapted first-line TKI selection in chronic-phase CML
Marginal Zone Lymphoma
Subtype-specific management of marginal zone lymphoma
Non-Hodgkin Lymphoma
NHL subtype classification and initial treatment approach
Dermatology Indications
Interactive sessions addressing the rapidly evolving biologic and small-molecule landscape in inflammatory skin disease.
Don't See Your Indication?
These are some of the therapeutic areas we cover — not all of them. We're continuously expanding our clinical programming. Reach out to discuss sessions for your area.
Get in Touch